Literature DB >> 10369473

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

J Galle1, U Zabel, U Hübner, A Hatzelmann, B Wagner, C Wanner, H H Schmidt.   

Abstract

The vasomotor and cyclic GMP-elevating activity of YC-1, a novel NO-independent activator of soluble guanylyl cyclase (sGC), was studied in isolated rabbit aortic rings and compared to that of the NO donor compounds sodium nitroprusside (SNP) and NOC 18. Similarly to SNP and NOC 18, YC-1 (0.3-300 microM) caused a concentration-dependent, endothelium-independent relaxation that was greatly reduced by the sGC inhibitor 1-H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ 10 microM; 59% inhibition of dilation induced by 100 microM YC-1) suggesting the activation of sGC as one mechanism of action. Preincubation with YC-1 (3 and 30 microM) significantly increased the maximal dilator responses mediated by endogenous NO in aortic rings that was released upon exposure to acetylcholine, and enhanced the dilator response to the exogenous NO-donors, SNP and NOC 18, by almost two orders of magnitude. Vasoactivity induced by SNP and YC-1 displayed different kinetics as evidenced by a longlasting inhibition by YC-1 (300 microM) on the phenylephrine (PE)-induced contractile response, which was not fully reversible even after extensive washout (150 min) of YC-1, and was accompanied by a long-lasting elevation of intracellular cyclic GMP content. In contrast, SNP (30 microM) had no effect on the vasoconstrictor potency of PE, and increases in intravascular cyclic GMP levels were readily reversed after washout of this NO donor compound. Surprisingly, YC-1 not only activated sGC, but also affected cyclic GMP metabolism, as it inhibited both cyclic GMP break down in aortic extracts and the activity of phosphodiesterase isoforms 1-5 in vitro. In conclusion, YC-1 caused persistent elevation of intravascular cyclic GMP levels in vivo by activating sGC and inhibiting cyclic GMP break down. Thus, YC-1 is a highly effective vasodilator compound with a prolonged duration of action, and mechanisms that are unprecedented for any previously known sGC activator.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369473      PMCID: PMC1565982          DOI: 10.1038/sj.bjp.0702495

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.

Authors:  W J Thompson; W L Terasaki; P M Epstein; S J Strada
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets.

Authors:  E Böhme; H Graf; G Schultz
Journal:  Adv Cyclic Nucleotide Res       Date:  1978

4.  Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.

Authors:  A Friebe; G Schultz; D Koesling
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

5.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Authors:  W P Arnold; C K Mittal; S Katsuki; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

6.  An improved assay of cyclic 3',5'-nucleotide phosphodiesterases with QAE-Sephadex columns.

Authors:  A C Bauer; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-03       Impact factor: 3.000

7.  Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.

Authors:  A Mülsch; J Bauersachs; A Schäfer; J P Stasch; R Kast; R Busse
Journal:  Br J Pharmacol       Date:  1997-02       Impact factor: 8.739

8.  Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.

Authors:  J W Wegener; I Gath; U Förstermann; H Nawrath
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

9.  Isosorbide dinitrate. Effect on the vasodilator response to nitroglycerin.

Authors:  R Zelis; D T Mason
Journal:  JAMA       Date:  1975-10-13       Impact factor: 56.272

10.  A model for the regulation of the calmodulin-dependent enzymes erythrocyte Ca2+-transport ATPase and brain phosphodiesterase by activators and inhibitors.

Authors:  K Gietzen; I Sadorf; H Bader
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

View more
  41 in total

1.  YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea.

Authors:  T L Hwang; C C Wu; C M Teng
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 2.  Isoforms of NO-sensitive guanylyl cyclase.

Authors:  Michael Russwurm; Doris Koesling
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

3.  KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channels.

Authors:  Rong-Jyh Lin; Bin-Nan Wu; Yi-Ching Lo; Kuo-Pyng Shen; Young-Tso Lin; Chun-Hsiung Huang; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 4.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

5.  The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.

Authors:  Séverine Roger; Cécile Badier-Commander; Jérôme Paysant; Alex Cordi; Tony J Verbeuren; Michel Félétou
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

6.  Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach.

Authors:  Michael Russwurm; Florian Mullershausen; Andreas Friebe; Ronald Jäger; Corina Russwurm; Doris Koesling
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

Review 7.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

8.  Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.

Authors:  Johannes-Peter Stasch; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Achim Feurer; Torsten Minuth; Elisabeth Perzborn; Matthias Schramm; Alexander Straub
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 9.  New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications.

Authors:  John Garthwaite
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

10.  A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.

Authors:  Wei-Ping Wu; Jing-Xia Hao; Ennio Ongini; Francesco Impagnatiello; Cristina Presotto; Zsuzsanna Wiesenfeld-Hallin; Xiao-Jun Xu
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.